Our ever‐increasing understanding of biological systems is providing a range of exciting
novel biological targets, whose modulation may enable novel therapeutic options for many …

Abstract Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the
treatment of type 2 diabetes due to their ability to reduce weight and attenuate …

Obesity and its comorbidities, such as type 2 diabetes mellitus and cardiovascular disease,
constitute growing challenges for public health and economies globally. The available …

Peptides are receiving increasing interest as clinical therapeutics. These highly tunable
molecules can be tailored to achieve desirable biocompatibility and biodegradability with …

Obesity and its comorbidities, such as type 2 diabetes, are pressing worldwide health
concerns. Available anti‐obesity treatments include weight loss pharmacotherapies and …

Metabolic syndrome (MS) features a constellation of central obesity, dyslipidemia, impaired
glucose metabolism and often hypertension joined by insulin resistance and chronic …

Obesity and type 2 diabetes mellitus (T2DM) are preconditions for the development of
metabolic syndrome, which is reaching pandemic levels worldwide, but there are still only a …

The metabolic syndrome (MetS) encompasses medical conditions such as obesity,
hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever …

The ever-increasing prevalence of obesity and Type 2 diabetes has necessitated the
development of newer and more effective approaches for achieving efficient glycemic …

Unsere sich stetig erweiternden Kenntnisse über biologische Systeme haben eine Vielzahl
an hoch interessanten neuen biologischen Zielstrukturen aufgedeckt, deren Modulation …